Bio

Bio


Dr. Chad Brodt specializes in the diagnosis and management of heart rhythm disorders. He performs catheter ablation to treat conditions of fast rhythms such as supraventricular tachycardia, atrial flutter, atrial fibrillation and ventricular tachycardia. In addition he performs implantation procedures of devices such as pacemakers for slow heart rhythms as well as defibrillators and biventricular pacing devices for individuals with heart failure or risk of fatal arrhythmias. He is currently interested in improving our understanding and utilization of low radiation techniques when performing electrophysiologic procedures. He is an active participant in the Stanford Arrhythmia Service's multiple ongoing clinical trials to further the advancement in this field. He collaborates directly with Stanford Cardiac Surgeons in pioneering new "hybrid" approaches to manage arrhythmias.

Clinical Focus


  • Clinical Cardiac Electrophysiology
  • Cardiovascular Disease

Academic Appointments


Professional Education


  • Fellowship:University of Miami Jackson Memorial Hospital Internal Med Residency (2014) FL
  • Board Certification: Clinical Cardiac Electrophysiology, American Board of Internal Medicine (2016)
  • Board Certification: Cardiovascular Disease, American Board of Internal Medicine (2015)
  • Fellowship:Stanford University Hospital (2015) CA
  • Board Certification: Internal Medicine, American Board of Internal Medicine (2012)
  • Residency:University of Miami Miller School of Medicine/Jackson Memorial Hospital (2011) FL
  • Medical Education:University of Sydney (2007) Australia
  • Board Certification, Clinical Cardiac Electrophysiology, American Board of Internal Medicine (2016)

Research & Scholarship

Clinical Trials


  • Pivotal Study Of A Dual Epicardial & Endocardial Procedure (DEEP) Approach Recruiting

    The objective of this study is to establish the safety and effectiveness of a dual epicardial and endocardial ablation procedure for patients presenting with Persistent Atrial Fibrillation or Longstanding Persistent Atrial Fibrillation

    View full details

  • Precision Event Monitoring for Patients With Heart Failure Using HeartLogic™ Recruiting

    The goal of the PREEMPT-HF study is to collect device and clinical event data to evaluate extended applications of the HeartLogicTM Heart Failure Diagnostic (HeartLogic) in a broad spectrum of heart failure (HF) patients with an implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D). There are no primary safety and/or efficacy endpoints for this study. Heart failure (HF) is a complex clinical syndrome with high morbidity, mortality, and economic burden. Chronic HF is persistent, gradually progressive, and punctuated by episodes of acute worsening leading to hospitalizations. Therefore, there remains an unmet clinical need to slow the progression of HF and prevent hospitalizations. HeartLogicTM, available in Boston Scientific cardiac resynchronization therapy devices and defibrillators (CRT-Ds and ICDs), combines novel sensor parameters such as heart sounds and respiration with other measurements like thoracic impedance, heart rate, and activity into a HeartLogic Index for the early detection of worsening HF. However, there is limited data on the association of HeartLogic with the risk of HF readmissions and tachyarrhythmias, or for phenotyping the broad spectrum of HF patients.

    View full details

  • Low Fluoroscopy Afib Ablation Registry Not Recruiting

    Prospective data collection of patients undergoing Atrial Fibrillation Ablation.

    Stanford is currently not accepting patients for this trial. For more information, please contact Gerri O'Riordan, BSN RN, 650 7255597.

    View full details

Publications

All Publications


  • Propagation velocity at atrial fibrillation sources: Go with the flow. International journal of cardiology Rogers, A. J., Bhatia, N. K., Brodt, C. R., Narayan, S. M. 2019

    View details for DOI 10.1016/j.ijcard.2019.04.007

    View details for PubMedID 30979605

  • SITES THAT CONTROL LARGER AREAS DURING ATRIAL FIBRILLATION MAY DETERMINE TERMINATION DURING ABLATION Bhatia, N. K., Hossainy, S., Rogers, A., Alhusseini, M., Brodt, C., Moosvi, N., Baykaner, T., Wang, P., Rappel, W., Narayan, S. ELSEVIER SCIENCE INC. 2019: 400
  • Low-fluoroscopy atrial fibrillation ablation with contact force and ultrasound technologies: a learning curve. Pragmatic and observational research Zei, P. C., Hunter, T. D., Gache, L. M., O'Riordan, G., Baykaner, T., Brodt, C. R. 2019; 10: 1–7

    Abstract

    Background: Fluoroscopy exposure during catheter ablation is a health hazard to patients and operators. This study presents the results of implementing a low-fluoroscopy workflow using modern contact force (CF) technologies in paroxysmal atrial fibrillation (PAF) ablation.Methods: A fluoroscopy reduction workflow was implemented and subsequent catheter ablations for PAF were evaluated. After vascular access with ultrasound guidance, a THERMOCOOL SMARTTOUCH Catheter (ST) was advanced into the right atrium. The decapolar catheter was placed without fluoroscopy. A double-transseptal puncture was performed under intracardiac echocardiography guidance. ST and mapping catheters were advanced into the left atrium. A left atrial map was created, and pulmonary vein (PV) isolation was confirmed via entrance and exit block before and after the administration of isoproterenol or adenosine.Results: Forty-three patients underwent PAF ablation with fluoroscopy reduction workflow (mean age: 66±9 years; 70% male), performed by five operators. Acute success rate (PV isolation) was 96.5% of PVs. One case of pericardial effusion, not requiring intervention, was the only acute complication. Mean procedure time was 217±42 minutes. Mean fluoroscopy time was 2.3±3.0 minutes, with 97.7% of patients having < 10 minutes and 86.0% having < 5 minutes. A significant downward trend over time was observed, suggesting a rapid learning curve for fluoroscopy reduction. Freedom from any atrial arrhythmias without reablation was 80.0% after a mean follow-up of 12±3 months.Conclusion: Low fluoroscopy time is achievable with CF technologies after a short learning curve, without compromising patient safety or effectiveness.

    View details for DOI 10.2147/POR.S181220

    View details for PubMedID 30666175

  • Structurally-based electrical predictors of atrial arrhythmias. International journal of cardiology Rogers, A. J., Moosvi, N. F., Brodt, C. R., Narayan, S. M. 2018

    View details for DOI 10.1016/j.ijcard.2018.12.002

    View details for PubMedID 30528625

  • A Novel Pacing Maneuver to Verify the Post-Pacing Interval Minus the Tachycardia Cycle Length While Adjusting for Decremental Conduction: Using 'Dual Chamber Entrainment' for Improved Supraventricular Tachycardia Discrimination. Heart rhythm Kaiser, D. W., Nasir, J. M., Liem, L. B., Brodt, C., Motonaga, K. S., Ceresnak, S. R., Turakhia, M. P., Dubin, A. M. 2018

    Abstract

    BACKGROUND: The post-pacing interval (PPI) minus the tachycardia cycle length (TCL) is frequently used to investigate tachycardias. However, a variety of issues (e.g. failure to entrain, decremental conduction, and oscillating TCLs) can make interpretation of the PPI-TCL challenging.OBJECTIVES: To investigate a novel maneuver to confirm the PPI-TCL value without using either the ventricular PPI or the TCL interval. To assess the ability of this maneuver to identify decremental conduction and differentiate supraventricular tachycardias.METHODS: We analyzed 77 intracardiac recordings from patients [age 25±20 years, 40 female] who underwent catheter ablation of AVNRT or orthodromic reciprocating tachycardia (ORT) with a concealed pathway. We calculated the PPI-TCL, the AH-corrected PPI-TCL, and estimated the PPI-TCL using "dual chamber entrainment" calculated as: [PPIV-TCL=Stim(AoV)+Stim(VoA)-PPIA].RESULTS: The PPI-TCL calculated by dual chamber entrainment highly correlated with the observed and AH-corrected PPI-TCL [R2=0.79 and 0.96, respectively, p<0.001]. A dual chamber entrainment PPI-TCL value of 80ms correctly differentiated all AVNRT from septal ORT cases, whereas the standard PPI-TCL and AH-corrected PPI-TCL methods were incorrect in 14% and 6% of cases, respectively. Dual chamber entrainment identified 3±10ms of additional decremental conduction beyond AH-prolongation, including four pathways with significant (>10ms) decrement.CONCLUSION: Dual chamber entrainment estimates the PPI-TCL value without using either the ventricular PPI or the TCL interval. This maneuver adjusts for all decremental conduction, including within concealed pathways, where a dual chamber entrainment PPI-TCL value >80ms favors AVNRT over ORT. This maneuver can be used to verify the observed PPI-TCL value in challenging cases.

    View details for DOI 10.1016/j.hrthm.2018.11.021

    View details for PubMedID 30465902

  • Effects of Transendocardial Stem Cell Injection on Ventricular Proarrhythmia in Patients with Ischemic Cardiomyopathy: Results from the POSEIDON and TAC-HFT Trials. Stem cells translational medicine Ramireddy, A., Brodt, C. R., Mendizabal, A. M., DiFede, D. L., Healy, C., Goyal, V., Alansari, Y., Coffey, J. O., Viles-Gonzalez, J. F., Heldman, A. W., Goldberger, J. J., Myerburg, R. J., Hare, J. M., Mitrani, R. D. 2017; 6 (5): 1366–72

    Abstract

    Transendocardial stem cell injection in patients with ischemic cardiomyopathy (ICM) improves left ventricular function and structure but has ill-defined effects on ventricular arrhythmias. We hypothesized that mesenchymal stem cell (MSC) implantation is not proarrhythmic. Post hoc analyses were performed on ambulatory ECGs collected from the POSEIDON and TAC-HFT trials. Eighty-eight subjects (mean age 61 ± 10 years) with ICM (mean EF 32.2% ± 9.8%) received treatment with MSC (n = 48), Placebo (n = 21), or bone marrow mononuclear cells (BMC) (n = 19). Heart rate variability (HRV) and ventricular ectopy (VE) were evaluated over 12 months. VE did not change in any group following MSC implantation. However, in patients with ≥ 1 VE run (defined as ≥ 3 consecutive premature ventricular complexes in 24 hours) at baseline, there was a decrease in VE runs at 12 months in the MSC group (p = .01), but not in the placebo group (p = .07; intergroup comparison: p = .18). In a subset of the MSC group, HRV measures of standard deviation of normal intervals was 75 ± 30 msec at baseline and increased to 87 ± 32 msec (p =.02) at 12 months, and root mean square of intervals between successive complexes was 36 ± 30 msec and increased to 58.2 ± 50 msec (p = .01) at 12 months. In patients receiving MSCs, there was no evidence for ventricular proarrhythmia, manifested by sustained or nonsustained ventricular ectopy or worsened HRV. Signals of improvement in ventricular arrhythmias and HRV in the MSC group suggest a need for further studies of the antiarrhythmic potential of MSCs. Stem Cells Translational Medicine 2017;6:1366-1372.

    View details for DOI 10.1002/sctm.16-0328

    View details for PubMedID 28252842

    View details for PubMedCentralID PMC5442721

  • Temporal relationship of conduction system disease and ventricular dysfunction in LMNA cardiomyopathy. Journal of cardiac failure Brodt, C., Siegfried, J. D., Hofmeyer, M., Martel, J., Rampersaud, E., Li, D., Morales, A., Hershberger, R. E. 2013; 19 (4): 233–39

    Abstract

    LMNA cardiomyopathy presents with electrocardiogram (ECG) abnormalities, conduction system disease (CSD), and/or arrhythmias before the onset of dilated cardiomyopathy (DCM). Knowing the time interval between the onset of CSD and its progression to DCM would help to guide clinical care.We evaluated family members from 16 pedigrees previously identified to carry LMNA mutations for the ages of onset of ECG abnormalities, CSD, or arrhythmia and of left ventricular enlargement (LVE) and/or systolic dysfunction. Of 103 subjects, 64 carried their family LMNA mutation, and 51 (79%) had ECG abnormalities with a mean age of onset of 41.2 years (range 18-76). Ventricular dysfunction was observed in 26 with a mean age of onset of 47.6 years (range 28-82); at diagnosis 9 had systolic dysfunction but no LVE, 5 had LVE but no systolic dysfunction, and 11 had DCM. Of 16 subjects identified with ECG abnormalities who later developed ventricular dysfunction, the median ages of onset by log-rank analyses were 41 and 48 years, respectively.ECG abnormalities preceded DCM with a median difference of 7 years. Clinical surveillance should occur at least annually in those at risk for LMNA cardiomyopathy with any ECG findings.

    View details for DOI 10.1016/j.cardfail.2013.03.001

    View details for PubMedID 23582089

    View details for PubMedCentralID PMC3699310